Topics:

Sanofi, Protein Sciences win flu jab nods in older adults

Tools

A couple of flu vaccine makers have new patient populations to target, thanks to a pair of recent FDA approvals in older adults. On Monday, the agency gave Sanofi ($SNY) the thumbs up to include additional efficacy data in its prescribing information for Fluzone High-Dose that demonstrate improved protection against the standard Fluzone trivalent in adults age 65 and older. And late last week, Connecticut-based Protein Sciences said U.S. regulators had green-lighted its egg-free flu vaccine, Flublok, for use in people age 50 and older. Release | Release

Comments